Equities Analysts Offer Predictions for AXSM FY2027 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2027 earnings per share estimates for Axsome Therapeutics in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $5.90 for the year, down from their previous forecast of $6.45. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($5.12) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' FY2028 earnings at $10.40 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same quarter last year, the firm posted ($1.32) EPS.

A number of other research firms have also weighed in on AXSM. Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a research note on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 target price on the stock. UBS Group reduced their price objective on Axsome Therapeutics from $107.00 to $105.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Robert W. Baird upped their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday. Royal Bank of Canada raised their target price on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an "outperform" rating in a research note on Friday, October 4th. Finally, StockNews.com cut shares of Axsome Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $124.93.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM traded down $0.46 during midday trading on Thursday, hitting $97.37. The company's stock had a trading volume of 651,974 shares, compared to its average volume of 621,649. Axsome Therapeutics has a 12-month low of $56.66 and a 12-month high of $105.00. The company has a market cap of $4.62 billion, a P/E ratio of -14.96 and a beta of 1.26. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.40 and a current ratio of 2.44. The business's 50 day simple moving average is $90.59 and its 200 day simple moving average is $84.05.

Insider Buying and Selling

In other news, Director Mark E. Saad sold 11,016 shares of the firm's stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares of the company's stock, valued at approximately $913,282.62. This trade represents a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Axsome Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company's stock valued at $298,474,000 after purchasing an additional 43,512 shares in the last quarter. FMR LLC increased its stake in shares of Axsome Therapeutics by 20.6% during the third quarter. FMR LLC now owns 1,088,087 shares of the company's stock worth $97,786,000 after buying an additional 185,951 shares during the period. Millennium Management LLC raised its holdings in Axsome Therapeutics by 1.4% in the second quarter. Millennium Management LLC now owns 739,819 shares of the company's stock valued at $59,555,000 after acquiring an additional 10,401 shares in the last quarter. Bellevue Group AG lifted its stake in Axsome Therapeutics by 7.9% in the first quarter. Bellevue Group AG now owns 685,476 shares of the company's stock worth $54,701,000 after acquiring an additional 50,104 shares during the last quarter. Finally, Hood River Capital Management LLC grew its holdings in Axsome Therapeutics by 5.4% during the 2nd quarter. Hood River Capital Management LLC now owns 549,066 shares of the company's stock worth $44,200,000 after acquiring an additional 28,316 shares in the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.